Literature DB >> 2951535

Inhibition of cytotoxicity to autologous tumor cells by the regional lymph node cells of patients with primary lung cancer.

C Kadoyama, H Kimura, Y Yamaguchi.   

Abstract

The regional lymph node (RL) cells of patients with primary lung cancer exhibited no cytotoxicity to autologous tumor cells in a 4-hr 51Cr-release assay, but when cultured in the presence of Interleukin 2 (IL2), the RL cells did become cytotoxic to those target cells. When RL cells were included in a cytotoxic test of IL2-activated RL cells (autologous killer T cells; AKT cells) and autologous target cells, the cytotoxicity of the AKT cells was significantly inhibited in 27 out of a total of 42 cases, but this suppression was observed against neither allogeneic effector cells (seven out of nine cases) nor natural killer cells (all seven cases tested). The cytotoxicity of AKT cells to allogeneic target cells was inhibited by RL cells in three out of six cases. Nylon-wool column separation indicated that the cell population adhering to the nylon wool mediated the suppressive effect of the RL cells. These data suggested the presence of nylon-wool-adherent suppressor cells in the regional lymph nodes of patients with primary lung cancer which suppress the cytotoxicity of autologous killer lymphocytes to autologous tumor cells.

Entities:  

Mesh:

Year:  1987        PMID: 2951535

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  2 in total

1.  Tumour-associated proliferative responses in vitro of regional lymph nodes draining solid cancers in man.

Authors:  T Mainou-Fowler; O Eremin
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer.

Authors:  Hideki Kimura; Yukiko Matsui; Aki Ishikawa; Takahiro Nakajima; Mitsuru Yoshino; Yuichi Sakairi
Journal:  Cancer Immunol Immunother       Date:  2014-09-28       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.